HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma (NASDAQ: HOOK) will host an investor call on June 4, 2024, at 4:15 p.m. ET to discuss promising preliminary results from its Phase 2 clinical trial of HB-200 in combination with pembrolizumab.
The data, presented at the American Society of Clinical Oncology 2024 Annual Meeting, focuses on progression-free survival and overall survival for patients with a Combined Positive Score (CPS) ≥20, targeting human papillomavirus 16 positive head and neck cancer.
The company's proprietary arenavirus platform underpins this new class of immunotherapeutics.
- The investor call will highlight promising preliminary data from HOOKIPA's Phase 2 clinical trial of HB-200.
- The trial focuses on progression-free survival and overall survival metrics, important indicators of a treatment's effectiveness.
- The focus on patients with a Combined Positive Score (CPS) ≥20 offers a targeted approach, which could lead to more effective treatments.
- The data will be presented at the American Society of Clinical Oncology 2024 Annual Meeting, a high-profile event that can enhance the company's visibility.
- HOOKIPA's proprietary arenavirus platform introduces a novel immunotherapeutic approach, potentially leading to significant advancements in cancer treatment.
- The results presented are preliminary, meaning they may change as more data becomes available.
- The focus on a specific subset of patients (CPS ≥20) may limit the generalizability of the results.
- No specific quantitative data on progression-free survival and overall survival rates were provided in the announcement, limiting the ability to fully assess the study's impact.
- There could be high expectations set by the 'promising' preliminary results, which, if unmet, may negatively impact stock performance.
- Company will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ≥20
- Conference call on Tuesday, June 4, at 4:15 p.m. ET
NEW YORK and VIENNA, May 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of HOOKIPA’s Executive Team will host an investor call on June 4, 2024, at 4:15 p.m. ET. Complete details and registration information are included below. The call will detail the Company’s Phase 2 clinical data of HB-200 in combination with pembrolizumab for the treatment of human papillomavirus 16 positive head and neck cancer, including preliminary progression-free survival and overall survival data for patients with CPS ≥20.
Call Details:
HOOKIPA HB-200 ASCO Data Update
Tuesday, June 4, 2024, 4:15 p.m. ET
Webcast Registration
Dial-in Registration
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other unnamed indications. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.
Find out more about HOOKIPA online at www.hookipapharma.com.
Forward Looking Statements
Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “anticipates”, “believes,” “expects,” “plans,” “potential,” “will,” “would” or similar expressions and the negative of those terms. Forward-looking statements in this press release include HOOKIPA’s statements regarding the potential of its product candidates to positively impact quality of life and alter the course of disease in the patients it seeks to treat, HOOKIPA’s plans, strategies, expectations and anticipated milestones for its preclinical and clinical programs, including the timing of initiating clinical trials and patient enrollment, the availability and timing of results from preclinical studies and clinical trials, the timing of regulatory filings, the expected safety profile of HOOKIPA’s product candidates, and the probability of successfully developing and receiving regulatory approval for its product candidates. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, plans and timelines for the preclinical and clinical development of its product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, the ability to initiate new clinical programs, the risk that the results of current preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical and clinical trials, including those for HB-200, HB-700, HB-400 and HB-500, the regulatory approval process, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, HOOKIPA’s ability to achieve the expected benefits of its strategic reprioritization and other matters that could affect the sufficiency of existing cash to fund operations. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see HOOKIPA’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as discussions of potential risks, uncertainties, and other important factors in HOOKIPA’s subsequent filings with the Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov and HOOKIPA’s website at http://hookipapharma.com/. In addition, any forward-looking statements represent HOOKIPA’s views only as of today and should not be relied upon as representing its views as of any subsequent date. HOOKIPA explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Availability of Other Information About HOOKIPA
Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.
For further information, please contact:
Investors and Media
Michael Kaiser
michael.kaiser@hookipapharma.com
+ 1 (917) 984-7537
FAQ
When is HOOKIPA Pharma hosting its investor call?
What will be discussed during HOOKIPA Pharma's investor call?
What is the focus of HOOKIPA Pharma's HB-200 clinical trial?
Where were HOOKIPA Pharma's HB-200 trial results presented?
What is significant about the CPS ≥20 patient group in HOOKIPA Pharma's trial?
